The role of gemcitabine for colorectal can has not been defined. Moore et al found that Gemcitabine, at the doses and schedule used in his study, did not demonstrate activity against advanced colorectal adenocarcinoma. A much later study from Columbia University(Saif et al) found that Gemcitabine has a modest activity in heavily pre-treated colorectal cancer patients and may be an option in good performance status patients. There are a number of reports and ongoing studies of gemcitabine in combination for colorectal cancer. A recent study, Gemcitabine in Treating Patients With Advanced Colorectal Cancer,, NCT00007943, was completed in 2009 but not published as of 2012.
MUHAMMAD WASIF SAIF, KRISTIN KALEY, ROBIN PENNEY, SUSAN HOTCHKISS, KOSTAS N. SYRIGOS and ALEXIOS S. STRIMPAKOS, The Efficacy of Gemcitabine as Salvage Treatment in Patients with Refractory Advanced Colorectal Cancer (CRC): A Single Institution Experience Anticancer Research September 2011 vol. 31 no. 9 2971-2974
Dennis F. Moore, Richard Pazdur, Karen Daugherty, Peter Tarassoff and James L. Abbruzzese Phase II study of gemcitabine in advanced colorectal adenocarcinoma Investigational New Drugs
Volume 10, Number 4 (1992), 323-325.
For Lay version see here